Outlook Therapeutics, Inc.OTLKNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank25
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-60.47M
↓ 23% vs avg
Percentile
P25
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
$-49.35M
Historical baseline
PeriodValueYoY Change
TTM$-60.47M+4.9%
2025$-63.58M+11.8%
2024$-72.09M-25.7%
2023$-57.38M+10.8%
2022$-64.36M-24.9%
2021$-51.51M-42.3%
2020$-36.20M-16.4%
2019$-31.11M-16.1%
2018$-26.80M+10.8%
2017$-30.03M-